Recent Updates
Recently added Catalysts
INDV Positive Sentiment Score: 70/100

Indivior Announces Q2/H1 2023 Financial Results Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending June 30, 2023. The earnings release, investor...

Key Takeaway: Indivior PLC announced its financial results for the second quarter and first half of 2023, showcasing a strong performance. The results were made public through an investor presentation and webcast, hosted by CEO Mark Crossley. The company remains dedicated to addressing substance use disorders by expanding its portfolio and offering global access to evidence-based treatment.

Market Sentiment Analysis

POSITIVE FACTORS

  • Indivior reported its financial results, indicating strong performance.
  • The company continues to focus on expanding its treatments for substance use disorders.
  • Indivior presents its commitment to providing access to evidence-based treatment globally.

Full Press Release Details

SLOUGH, United Kingdom , and RICHMOND, Va. , July 27, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV ) today announced its financial results for the period ending June 30, 2023 . The earnings release, investor presentation and webcast are available at www.indivior.com .
There will be a live webcast presentation at 13:00 BST ( 8:00 am EST ) hosted by Mark Crossley , CEO. The details are below.
Webcast link: https://edge.media-server.com/mmc/p/z4yh2znf Participants may access the presentation telephonically by registering with the following link: https://register.vevent.com/register/BI80255ae130d847e3944c2584e201ae3e
(Please note this is a change from prior calls - registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration)
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid use disorder treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and cooccurring disorders of SUD. Headquartered in the United States in Richmond, VA , Indivior employs more than 1,000 individuals globally and its portfolio of products is available in 39 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior .

21 %

Frequently Asked Questions

What date were Indivior's Q2 2023 financial results announced?

Indivior announced its Q2 2023 financial results on July 27, 2023.

Who will host the live webcast presentation by Indivior?

Mark Crossley, the CEO, will host the live webcast presentation.

What is Indivior's main focus as a pharmaceutical company?

Indivior focuses on developing treatments for substance use disorders and mental illnesses.

How many countries is Indivior's product portfolio available in?

Indivior's product portfolio is available in 39 countries worldwide.

How many employees does Indivior have globally?

Indivior employs over 1,000 individuals globally.

Last updated: Jul 27, 2023